162 related articles for article (PubMed ID: 23607207)
21. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE.
Cheung IY; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):210-2. PubMed ID: 11464887
[TBL] [Abstract][Full Text] [Related]
22. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
[TBL] [Abstract][Full Text] [Related]
23. [Significance of application of immunocytochemical detection of GD2 antigen in bone marrow in neuroblastoma patients].
Bolek-Marzec K; Balwierz W; Wieczorek A; Szewczyk K
Przegl Lek; 2010; 67(6):409-12. PubMed ID: 21344771
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
25. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma.
Longo L; Borghini S; Schena F; Parodi S; Albino D; Bachetti T; Da Prato L; Truini M; Gambini C; Tonini GP; Ceccherini I; Perri P
Int J Oncol; 2008 Nov; 33(5):985-91. PubMed ID: 18949361
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
[TBL] [Abstract][Full Text] [Related]
27. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
28. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma.
Bozzi F; Collini P; Aiello A; Barzanò E; Gambirasio F; Podda M; Meazza C; Ferrari A; Luksch R
Anticancer Res; 2008; 28(3A):1565-9. PubMed ID: 18630512
[TBL] [Abstract][Full Text] [Related]
31. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract][Full Text] [Related]
32. Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow.
Méhes G; Luegmayr A; Ambros IM; Ladenstein R; Ambros PF
Clin Cancer Res; 2001 Jul; 7(7):1969-75. PubMed ID: 11448912
[TBL] [Abstract][Full Text] [Related]
33. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.
Ball NS; King PH
Clin Cancer Res; 1997 Oct; 3(10):1859-65. PubMed ID: 9815574
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
35. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
Berois N; Blanc E; Ripoche H; Mergui X; Trajtenberg F; Cantais S; Barrois M; Dessen P; Kågedal B; Bénard J; Osinaga E; Raguénez G
Clin Chem; 2006 Sep; 52(9):1701-12. PubMed ID: 16873292
[TBL] [Abstract][Full Text] [Related]
36. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
[TBL] [Abstract][Full Text] [Related]
39. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
[TBL] [Abstract][Full Text] [Related]
40. Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma.
de Pontual L; Trochet D; Bourdeaut F; Thomas S; Etchevers H; Chompret A; Minard V; Valteau D; Brugieres L; Munnich A; Delattre O; Lyonnet S; Janoueix-Lerosey I; Amiel J
Eur J Cancer; 2007 Nov; 43(16):2366-72. PubMed ID: 17765533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
